{"transactions":[{"id":3633,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T23:09:24.000Z","date":"2026-09-03","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":104954,"derivative":{"exercise_price":12.95,"exercise_date":"2020-03-19","expiration_date":"2029-03-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-382277","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526382277/ownership.xml","form_type":"4"}},{"id":3632,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:09:24.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":208.65,"value":2086500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-382277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526382277/ownership.xml","form_type":"4"}},{"id":3631,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-09-03T23:09:24.000Z","date":"2026-09-03","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":12.95,"value":129500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-382277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526382277/ownership.xml","form_type":"4"}},{"id":791801,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-06T00:34:35.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":false,"shares":233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."}],"balance_after":114954,"derivative":{"exercise_price":12.95,"exercise_date":"2020-03-19","expiration_date":"2029-03-19","underlying":"Common Stock","underlying_shares":233},"source":{"system":"sec-edgar","filing":"0001193125-26-207148","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526207148/ownership.xml","form_type":"4"}},{"id":791800,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-06T00:34:35.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":4517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."}],"balance_after":115187,"derivative":{"exercise_price":12.95,"exercise_date":"2020-03-19","expiration_date":"2029-03-19","underlying":"Common Stock","underlying_shares":4517},"source":{"system":"sec-edgar","filing":"0001193125-26-207148","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526207148/ownership.xml","form_type":"4"}},{"id":791799,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-06T00:34:35.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":233,"price":228.18,"value":53165.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-207148","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526207148/ownership.xml","form_type":"4"}},{"id":791798,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-06T00:34:35.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":true,"shares":233,"price":12.95,"value":3017.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."}],"balance_after":233,"source":{"system":"sec-edgar","filing":"0001193125-26-207148","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526207148/ownership.xml","form_type":"4"}},{"id":791797,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-06T00:34:35.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":4517,"price":227.94,"value":1029604.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-207148","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526207148/ownership.xml","form_type":"4"}},{"id":791796,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-06T00:34:35.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":4517,"price":12.95,"value":58495.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed."}],"balance_after":4517,"source":{"system":"sec-edgar","filing":"0001193125-26-207148","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526207148/ownership.xml","form_type":"4"}},{"id":801907,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Performance Stock Units","published_at":"2026-04-24T01:02:45.000Z","date":"2026-04-21","kind":"grant","planned":false,"acquired":true,"shares":8669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date."}],"balance_after":8669,"derivative":{"underlying":"Common Stock","underlying_shares":8669},"source":{"system":"sec-edgar","filing":"0001193125-26-174419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526174419/ownership.xml","form_type":"4"}},{"id":877372,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-28T00:10:03.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":19663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan (\"2025 Plan\")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant."}],"balance_after":19663,"derivative":{"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":19663},"source":{"system":"sec-edgar","filing":"0001193125-26-083605","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526083605/ownership.xml","form_type":"4"}},{"id":877371,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-28T00:00:06.000Z","date":"2026-02-26","kind":"exercise","planned":true,"acquired":false,"shares":35378,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":0,"derivative":{"exercise_price":2.85,"exercise_date":"2019-03-12","expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":35378},"source":{"system":"sec-edgar","filing":"0001193125-26-083586","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526083586/ownership.xml","form_type":"4"}},{"id":877370,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-28T00:00:06.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":35378,"price":161.88,"value":5726990.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.10 and $163.42."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-083586","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526083586/ownership.xml","form_type":"4"}},{"id":877369,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-28T00:00:06.000Z","date":"2026-02-26","kind":"exercise","planned":true,"acquired":true,"shares":35378,"price":2.85,"value":100827.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":35378,"source":{"system":"sec-edgar","filing":"0001193125-26-083586","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312526083586/ownership.xml","form_type":"4"}},{"id":1034650,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-22T23:00:03.000Z","date":"2025-09-22","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed."}],"balance_after":35378,"derivative":{"exercise_price":2.85,"exercise_date":"2019-03-12","expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-25-211788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525211788/ownership.xml","form_type":"4"}},{"id":1034649,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-09-22T23:00:03.000Z","date":"2025-09-22","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":115.96,"value":1159600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $115.11 and $116.55."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-211788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525211788/ownership.xml","form_type":"4"}},{"id":1034648,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-09-22T23:00:03.000Z","date":"2025-09-22","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":2.85,"value":28500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-25-211788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525211788/ownership.xml","form_type":"4"}},{"id":1037866,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-17T23:00:04.000Z","date":"2025-09-16","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."}],"balance_after":0,"derivative":{"exercise_price":4.85,"exercise_date":"2018-09-13","expiration_date":"2027-09-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-206494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525206494/ownership.xml","form_type":"4"}},{"id":1037865,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-17T23:00:04.000Z","date":"2025-09-16","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."}],"balance_after":0,"derivative":{"exercise_price":4.95,"exercise_date":"2018-03-15","expiration_date":"2027-03-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-206494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525206494/ownership.xml","form_type":"4"}},{"id":1037864,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-09-17T23:00:04.000Z","date":"2025-09-16","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":114.23,"value":4569200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $112.93 and $116.87."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-206494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525206494/ownership.xml","form_type":"4"}},{"id":1037863,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-09-17T23:00:04.000Z","date":"2025-09-16","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":4.85,"value":72750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001193125-25-206494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525206494/ownership.xml","form_type":"4"}},{"id":1037862,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-09-17T23:00:04.000Z","date":"2025-09-16","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":4.95,"value":123750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001193125-25-206494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525206494/ownership.xml","form_type":"4"}},{"id":1037861,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-09-17T23:00:04.000Z","date":"2025-09-16","kind":"sale","planned":true,"acquired":false,"shares":5783,"price":116.19,"value":671926.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the sale of underlying shares of previously exercised stock options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the sale price of all shares in an open market transaction."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-206494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000119312525206494/ownership.xml","form_type":"4"}},{"id":1116395,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T23:00:05.000Z","date":"2025-06-09","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":0,"derivative":{"exercise_price":8.02,"exercise_date":"2017-05-27","expiration_date":"2026-05-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-084556","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025084556/ownership.xml","form_type":"4"}},{"id":1116394,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-06-10T23:00:05.000Z","date":"2025-06-09","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":110.44,"value":2761000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24."}],"balance_after":5783,"source":{"system":"sec-edgar","filing":"0000950170-25-084556","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025084556/ownership.xml","form_type":"4"}},{"id":1116393,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-06-10T23:00:05.000Z","date":"2025-06-09","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":8.02,"value":200500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":30783,"source":{"system":"sec-edgar","filing":"0000950170-25-084556","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025084556/ownership.xml","form_type":"4"}},{"id":1132036,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-29T01:52:55.000Z","date":"2025-05-28","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":0,"derivative":{"exercise_price":6.47,"exercise_date":"2016-09-15","expiration_date":"2025-09-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-078552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025078552/ownership.xml","form_type":"4"}},{"id":1132035,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-29T01:52:55.000Z","date":"2025-05-27","kind":"exercise","planned":true,"acquired":false,"shares":20673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":0,"derivative":{"exercise_price":6.47,"exercise_date":"2016-09-15","expiration_date":"2025-09-15","underlying":"Common Stock","underlying_shares":20673},"source":{"system":"sec-edgar","filing":"0000950170-25-078552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025078552/ownership.xml","form_type":"4"}},{"id":1132034,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-29T01:52:55.000Z","date":"2025-05-28","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":103.45,"value":2069000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $102.67 and $104.22."}],"balance_after":5783,"source":{"system":"sec-edgar","filing":"0000950170-25-078552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025078552/ownership.xml","form_type":"4"}},{"id":1132033,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-29T01:52:55.000Z","date":"2025-05-28","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":6.47,"value":129400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":25783,"source":{"system":"sec-edgar","filing":"0000950170-25-078552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025078552/ownership.xml","form_type":"4"}},{"id":1132032,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-29T01:52:55.000Z","date":"2025-05-27","kind":"sale","planned":true,"acquired":false,"shares":20673,"price":104.66,"value":2163636.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $103.96 and $106.44."}],"balance_after":5783,"source":{"system":"sec-edgar","filing":"0000950170-25-078552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025078552/ownership.xml","form_type":"4"}},{"id":1132031,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-29T01:52:55.000Z","date":"2025-05-27","kind":"exercise","planned":true,"acquired":true,"shares":20673,"price":6.47,"value":133754.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":26456,"source":{"system":"sec-edgar","filing":"0000950170-25-078552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025078552/ownership.xml","form_type":"4"}},{"id":1246405,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Performance Stock Units","published_at":"2025-02-26T00:53:23.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":10769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date."}],"balance_after":10769,"derivative":{"underlying":"Common Stock","underlying_shares":10769},"source":{"system":"sec-edgar","filing":"0000950170-25-027065","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025027065/ownership.xml","form_type":"4"}},{"id":1246404,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-26T00:53:23.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":10769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":10769,"derivative":{"underlying":"Common Stock","underlying_shares":10769},"source":{"system":"sec-edgar","filing":"0000950170-25-027065","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025027065/ownership.xml","form_type":"4"}},{"id":1246403,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-26T00:53:23.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":10875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 21, 2029."}],"balance_after":10875,"derivative":{"exercise_price":137.75,"expiration_date":"2035-02-20","underlying":"Common Stock","underlying_shares":10875},"source":{"system":"sec-edgar","filing":"0000950170-25-027065","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017025027065/ownership.xml","form_type":"4"}},{"id":1436939,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T23:27:21.000Z","date":"2024-08-09","kind":"exercise","planned":true,"acquired":false,"shares":47739,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this year."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":0,"derivative":{"exercise_price":4.04,"exercise_date":"2015-12-29","expiration_date":"2024-12-29","underlying":"Common Stock","underlying_shares":47739},"source":{"system":"sec-edgar","filing":"0000950170-24-094967","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024094967/ownership.xml","form_type":"4"}},{"id":1436938,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-09T23:27:21.000Z","date":"2024-08-09","kind":"sale","planned":true,"acquired":false,"shares":47739,"price":84.26,"value":4022488.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $82.705 and $85.975."}],"balance_after":5783,"source":{"system":"sec-edgar","filing":"0000950170-24-094967","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024094967/ownership.xml","form_type":"4"}},{"id":1436937,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-09T23:27:21.000Z","date":"2024-08-09","kind":"exercise","planned":true,"acquired":true,"shares":47739,"price":4.04,"value":192865.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this year."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":53522,"source":{"system":"sec-edgar","filing":"0000950170-24-094967","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024094967/ownership.xml","form_type":"4"}},{"id":1499240,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-30T00:12:56.000Z","date":"2024-05-29","kind":"exercise","planned":false,"acquired":false,"shares":13693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options."}],"balance_after":0,"derivative":{"exercise_price":1.3,"exercise_date":"2015-08-15","expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":13693},"source":{"system":"sec-edgar","filing":"0000950170-24-066177","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024066177/ownership.xml","form_type":"4"}},{"id":1499239,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-05-30T00:12:56.000Z","date":"2024-05-29","kind":"sale","planned":false,"acquired":false,"shares":7910,"price":74.3127,"value":587813.457,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the subsequent sale of a portion of the underlying shares of the aforementioned exercise of stock options by the reporting person through a \"sell to cover\" transaction to satisfy tax withholding obligations and costs in connection with the aforementioned exercise of stock options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $73.99 and $74.52."}],"balance_after":5783,"source":{"system":"sec-edgar","filing":"0000950170-24-066177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024066177/ownership.xml","form_type":"4"}},{"id":1499238,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-05-30T00:12:56.000Z","date":"2024-05-29","kind":"exercise","planned":false,"acquired":true,"shares":13693,"price":1.3,"value":17800.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options prior to the 10-year expiration date of such options."}],"balance_after":13693,"source":{"system":"sec-edgar","filing":"0000950170-24-066177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024066177/ownership.xml","form_type":"4"}},{"id":1556440,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-01T22:46:51.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":24662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options immediately prior to the 10-year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":0,"derivative":{"exercise_price":1.3,"exercise_date":"2014-10-03","expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":24662},"source":{"system":"sec-edgar","filing":"0000950170-24-039617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024039617/ownership.xml","form_type":"4"}},{"id":1556439,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-01T22:46:51.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":24662,"price":77.242,"value":1904942.204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-039617","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024039617/ownership.xml","form_type":"4"}},{"id":1556438,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-04-01T22:46:51.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":24662,"price":1.3,"value":32060.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of stock options immediately prior to the 10-year expiration date of such options."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Such transaction was pursuant to a pre-approved 10b5-1 plan."}],"balance_after":24662,"source":{"system":"sec-edgar","filing":"0000950170-24-039617","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024039617/ownership.xml","form_type":"4"}},{"id":1610149,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-29T23:34:06.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":18027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":18027,"derivative":{"underlying":"Common Stock","underlying_shares":18027},"source":{"system":"sec-edgar","filing":"0000950170-24-023373","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024023373/ownership.xml","form_type":"4"}},{"id":1610148,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-02-29T23:34:06.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":32825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 27, 2028."}],"balance_after":32825,"derivative":{"exercise_price":84,"expiration_date":"2034-02-26","underlying":"Common Stock","underlying_shares":32825},"source":{"system":"sec-edgar","filing":"0000950170-24-023373","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000095017024023373/ownership.xml","form_type":"4"}},{"id":1969307,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Restricted Stock Units","published_at":"2023-03-06T23:15:35.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":23491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":23491,"derivative":{"underlying":"Common Stock","underlying_shares":23491},"source":{"system":"sec-edgar","filing":"0001209191-23-016458","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000120919123016458/doc4.xml","form_type":"4"}},{"id":1969306,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-03-06T23:15:35.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":41424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 2, 2027."}],"balance_after":41424,"derivative":{"exercise_price":65.32,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":41424},"source":{"system":"sec-edgar","filing":"0001209191-23-016458","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000120919123016458/doc4.xml","form_type":"4"}},{"id":2344826,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Restricted Stock Units","published_at":"2022-03-08T22:03:14.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":47990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":47990,"derivative":{"underlying":"Common Stock","underlying_shares":47990},"source":{"system":"sec-edgar","filing":"0001209191-22-017159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000120919122017159/doc4.xml","form_type":"4"}},{"id":2344825,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-08T22:03:14.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":89405,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 4, 2026."}],"balance_after":89405,"derivative":{"exercise_price":29.91,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":89405},"source":{"system":"sec-edgar","filing":"0001209191-22-017159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000120919122017159/doc4.xml","form_type":"4"}},{"id":2512954,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-11-16T00:54:01.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":41638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will start to vest one year from November 12, 2021 and then will vest in substantially equal quarterly installments over three years such that the option will be fully vested on November 12, 2025."}],"balance_after":41638,"derivative":{"exercise_price":39.26,"expiration_date":"2031-11-11","underlying":"Common Stock","underlying_shares":41638},"source":{"system":"sec-edgar","filing":"0001209191-21-064588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000120919121064588/doc4.xml","form_type":"4"}},{"id":2800236,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2021-03-10T02:46:20.000Z","date":"2021-03-05","kind":"grant","acquired":true,"shares":22163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 5, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 5, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":22163,"derivative":{"underlying":"Common Stock","underlying_shares":22163},"source":{"system":"sec-edgar","filing":"0000899243-21-010807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000089924321010807/doc4.xml","form_type":"4"}},{"id":2800235,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-10T02:46:20.000Z","date":"2021-03-05","kind":"grant","acquired":true,"shares":41638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 5, 2025."}],"balance_after":41638,"derivative":{"exercise_price":65.02,"expiration_date":"2031-03-04","underlying":"Common Stock","underlying_shares":41638},"source":{"system":"sec-edgar","filing":"0000899243-21-010807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000089924321010807/doc4.xml","form_type":"4"}},{"id":2933229,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-23T23:08:54.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":14767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":14767,"derivative":{"underlying":"Common Stock","underlying_shares":14767},"source":{"system":"sec-edgar","filing":"0001104659-20-139275","document":"tm2039202-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000110465920139275/tm2039202-2_4seq1.xml","form_type":"4/A","original_submission_date":"2020-03-19"}},{"id":2933228,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-23T23:08:54.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":48237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024."}],"balance_after":48237,"derivative":{"exercise_price":45.14,"expiration_date":"2030-03-16","underlying":"Common Stock","underlying_shares":48237},"source":{"system":"sec-edgar","filing":"0001104659-20-139275","document":"tm2039202-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000110465920139275/tm2039202-2_4seq1.xml","form_type":"4/A","original_submission_date":"2020-03-19"}},{"id":3200910,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-20T01:19:31.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":18645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the \"Plan\"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant."}],"balance_after":18645,"derivative":{"underlying":"Common Stock","underlying_shares":18645},"source":{"system":"sec-edgar","filing":"0001179110-20-004010","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000117911020004010/edgar.xml","form_type":"4"}},{"id":3200909,"issuer":{"id":2469,"kind":"organization","name":"Axsome Therapeutics, Inc.","symbol":"AXSM"},"owners":[{"id":2470,"kind":"person","name":"Jacobson Mark L.","position":1,"cik":"0001805812","reported_name":"Jacobson Mark L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-20T01:19:31.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":60880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024."}],"balance_after":60880,"derivative":{"exercise_price":45.14,"expiration_date":"2030-03-16","underlying":"Common Stock","underlying_shares":60880},"source":{"system":"sec-edgar","filing":"0001179110-20-004010","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805812/000117911020004010/edgar.xml","form_type":"4"}}]}